Letter: The Q425R Variant in Chronic Hepatitis Delta—Distinguishing Cirrhosis Prevalence From Portal Hypertension Severity
Alimentary Pharmacology & Therapeutics · 03.10.2026
DOI: 10.1111/apt.71030 ↗Kurz gefasst
Leserbrief in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 03.10.2026. Verfasst von Dandan Weng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Affiliated Yangming Hospital of Ningbo University, Yuyao, Zhejiang, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Infectious Diseases, Affiliated Yangming Hospital of Ningbo University, Yuyao, Zhejiang, China.
ORCID-Profile: Dandan Weng
Zitieren
APA
Weng, D., & Zhang, P. (2026). Letter: The Q425R Variant in Chronic Hepatitis Delta—Distinguishing Cirrhosis Prevalence From Portal Hypertension Severity. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.71030
Vancouver
Weng D, Zhang P. Letter: The Q425R Variant in Chronic Hepatitis Delta—Distinguishing Cirrhosis Prevalence From Portal Hypertension Severity. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.71030
BibTeX
@article{Weng2026,
author = {Weng, Dandan and Zhang, Pingping},
title = {Letter: The Q425R Variant in Chronic Hepatitis Delta—Distinguishing Cirrhosis Prevalence From Portal Hypertension Severity},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.71030}
}
EUVIMED